Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- Pharmaceuticals
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 203418
License Grant
Licensor grants an exclusive, worldwide right and license under the Thalidomide Patent Rights and the Mixed Patent Rights, to make, have made, use, lease, offer for sale, sell and import Products and practice Licensed Methods in the field.
License Property
The patents relate to Thalidomide. The term Thalidomide shall mean a compound with the chemical structure described as 2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, or as otherwise defined in the Merck Index, entry 9390, 12th ed., and pharmaceutically acceptable salts thereof.
The term product shall mean any article of manufacture, substance, material, chemical, formulation or composition for use in the Field which is or includes Thalidomide as an active ingredient, including, without limitation, a composition that comprises Thalidomide and a non-steroidal anti-inflammatory compound(s). The Product expressly excludes Thalidomide analogs.
Field of Use
The term Field shall mean the use of Thalidomide, alone or in combination, in humans or animals, including without limitation any and all diagnostic, prophylactic, therapeutic, and research and development uses.
THALOMID(R) (thalidomide), Licensee's lead product is currently marketed for the treatment of erythema nodosum leprosum, or ENL, but more widely used off-label for treating multiple myeloma and other cancers.
Erythema nodosum leprosum is one of the most frequently used terms in the science of leprosy. It is an immune-mediated complication of leprosy presenting with inflammatory skin nodules. Immune complex production and deposition as well as complement activation have long been regarded as the principal etiology of ENL. ENL is characterised by an inflammatory infiltrate of neutrophils with vasculitis. There is deposition of immune complexes and complement together with Mycobacterium leprae antigens in the skin.
IPSCIO Record ID: 26020
License Grant
Licensor, a non-profit health care organization, hereby grants to Licensee a world-wide, exclusive royalty-bearing license, with the right to sublicense under Licensors entire right, title and interest in and to the Analog Patents, to make, use, offer for sale, sell, import, practice, and otherwise dispose of any and all Licensed Products and Licensed Methods in the Analog Field.
License Property
Licensed Product means and includes (a) any Amino Thalidomide Product; (b) any Revimid Product; (c) any product, the making, using, offering for sale, sale, or importation of which, by an unlicensed third party, would infringe any of the Analog Patents; and (d) any product that is disclosed as a species or encompassed by a genus described at column 7, line 1 through column 11, line 50 of U.S. Patent No. 5,712,291 which will not be unreasonably interpreted to encompass products that are not genuine thalidomide analogues including, without limitation, compounds currently referred to as SelCids(TM).
Thalidomide means the chemical described as 2-(2,6- Dioxo-3-piperidinyl)-lH- isoindole-1,3(2H)-dione
Thalidomide Analog means and includes any and all analogs, metabolites, precursors, and hydrolysis products of Thalidomide, and all stereoisomers of each of the foregoing, including without limitation (a) all such compounds disclosed, generically or specifically, or claimed by any of the Analog Patents, (b) Amino Thalidomide and all stereoisomers and metabolites thereof; and (c) Revimid, and all stereoisomers and metabolites thereof.
Thalidomide is used along with dexamethasone to treat multiple myeloma in people who have been recently found to have this disease. It is also used alone or with other medications to treat and prevent skin symptoms of erythema nodosum leprosum (ENL; episodes of skin sores, fever, and nerve damage that occur in people with Hansen's disease [leprosy]). Thalidomide is in a class of medications called immunomodulatory agents. It treats multiple myeloma by strengthening the immune system to fight cancer cells. It treats ENL by blocking the action of certain natural substances that cause swelling.
Field of Use
Analog Field means and includes any and all uses of any Thalidomide Analog, alone or in combination, including without limitation (a) in humans and animals, and (b) for any and all diagnostic, prophylactic, therapeutic, and research and development uses.
IPSCIO Record ID: 26487
License Grant
The Licensor hereby grants to Switzerland company an exclusive (including as to Licensor and its Affiliates) royalty-bearing license to register, distribute, market, use and sell the Products in the Territory under the Licensor'd Patent Rights and the Licensor's Technology.
License Property
Products shall mean each article of manufacture, substance, material, chemical, formulation or composition which is or includes Thalidomide as an active ingredient, including, without limitation, any composition that comprises Thalidomide and a non-steroidal anti-inflammatory compound(s).
The term Products expressly excludes Thalidomide analogs. The product is currently is under review by the European Medicines Agency (EMEA) to treat patients with newly diagnosed multiple myeloma. Multiple myeloma (also known as MM, myeloma, plasma cell myeloma, or as Kahler's disease after Otto Kahler) is a type of cancer of plasma cells which are immune system cells in bone marrow that produce antibodies. Myeloma is regarded as incurable, but remissions may be induced with steroids, chemotherapy, thalidomide and stem cell transplants. Myeloma is part of the broad group of diseases called hematological malignancies.
IPSCIO Record ID: 230821
License Grant
Licensor, a not-for-profit pediatric health care and biomedical research services holding company, hereby grants to Licensee an exclusive worldwide right and license in the Non-Thalidomide Field, to make, have made, use, lease, and sell the Licensed Products and to practice the Licensed Processes under the Patent Rights. Licensor shall retain a royalty-free, nonexclusive, irrevocable license to practice the Patent Rights for research purposes only.
License Property
A Licensed Product shall mean any product or part thereof which does not contain Thalidomide, alone or in combination, and which
A Licensed Process shall mean any process with application solely in the Non-Thalidomide Field and which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights.
Field of Use
Non-Thalidomide Field shall mean the use of any compound other than Thalidomide, alone or in combination, in humans or animals, including without limitation any and all diagnostic, prophylactic, therapeutic, and research and development uses.
Thalidomide may have use in treating diseases fed by the growth of tiny blood vessels – a growth process known as angiogenesis.
Licensee licensed the use of Thalidomide for cancer and other antiangiogenic mediated diseases from Licensor, and conducted four Phase II clinical trials and secured two orphan drug indications for the use of thalidomide in certain cancers.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
